|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Vanderbilt University National Institute on Aging (NIA) |
|---|---|
| Information provided by: | Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT00392795 |
Purpose
The primary purpose of this proposal will be to identify potentially modifiable risk factors of long-term cognitive impairment (i.e. development of delirium and exposure to sedative and analgesic medications) in ICU patients. The investigators will quantify the independent contribution of these risk factors to the incidence of long-term cognitive impairment, controlling for other established risk factors including age, pre-existing cognitive impairment, and apolipoprotein E (apoE) genotype. Quantifying the contributions of these modifiable risk factors will pave the way for the development of preventive and/or treatment strategies to reduce the incidence, severity and/or duration of long-term cognitive impairment and improve functional recovery for patients with critical illness.
| Condition |
|---|
|
Delirium Cognition Disorders Dementia |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors |
| Estimated Enrollment: | 800 |
| Study Start Date: | January 2007 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
Among Intensive Care Unit (ICU) survivors, subsequent cognitive and functional decline are the greatest threats to meaningful recovery. Six small cohorts indicate that an alarming 30% to 80% of the increasingly millions of ICU survivors develop an acquired long-term cognitive impairment (LTCI) functionally equivalent to mild/moderate dementia that may last years. Additionally, major deficits in health-related quality of life (HRQL), functional status, and an "ICU accelerated" frailty are common, especially in the elderly. A leading and potentially modifiable risk factor for these devastating outcomes may be ICU delirium, which is a predictor of higher mortality, higher cost, and poor cognitive function at discharge. Additionally, heavy and prolonged exposure to potent psychoactive medications routinely administered in high doses to ventilated patients may have lasting yet preventable cognitive and functional effects. In this proposal, Aims 1 and 3 will determine whether delirium is an independent risk factor for the incidence, severity, and/or duration of LTCI (Aim 1) and impaired HRQL (Aim 3) in ICU survivors. Likewise, Aims 2 and 4 will determine whether degree of exposure to sedative and analgesic medications in ICU patients is an independent risk factor for the incidence, severity, and/or duration of LTCI (Aim 2) and impaired HRQL (Aim 4). The study will be a prospective cohort study enrolling 800 mechanically ventilated medical and surgical patients from 3 diverse medical centers over a 39 month period with comprehensive follow-up testing at 3 and 12 months after hospital discharge. This study will quantify whether delirium and sedative/analgesic exposure are indeed risk factors for LTCI and HRQL, controlling for other covariates such as age, medical versus surgical ICU admission, pre-existing cognitive impairment, sepsis, and apoE genotype. This will pave the way for the development of preventive and/or treatment strategies to reduce long-term cognitive impairment and improve the functional recovery of older and younger ICU patients for decades to come. Major threats to recovery for ICU survivors are acquired cognitive and functional decline that can last years, especially in older patients. To pave the way for future preventive and interventional strategies, the cohort will determine to what degree delirium and potent sedatives and analgesics are risk factors for long-term cognitive impairment and functional decline following critical illness.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Medical and Surgical ICUs
Inclusion Criteria:
Exclusion Criteria:
Patients who meet the inclusion criteria will be excluded if they meet any of the following criteria:
Contacts and Locations| Contact: Meredith A Gambrell, BA | 615-936-3702 | meredith.gambrell@vanderbilt.edu |
| Contact: Brenda T Pun, RN, ACNP | 919-484-3964 | brenda.pun@vanderbilt.edu |
| United States, Tennessee | |
| Saint Thomas Hospital | Recruiting |
| Nashville, Tennessee, United States, 37205 | |
| Contact: Jan Dunn, RN, MSN 615-222-4356 JDUNN@stthomas.org | |
| Principal Investigator: Angelo Canonico, MD | |
| Vanderbilt University Medical Center | Recruiting |
| Nashville, Tennessee, United States, 37232 | |
| Contact: Joyce Okahashi, RN 615-936-0009 joyce.okahashi@vanderbilt.edu | |
| Principal Investigator: Pratik P Pandharipande, MD, MSCI | |
| Principal Investigator: | E Wesley Ely, MD, MPH | Vanderbilt University/VA TN Valley GRECC |
More Information
| Responsible Party: | Vanderbilt University Medical Center ( E. Wesley Ely, MD, MPH - PI ) |
| Study ID Numbers: | AG072472 01A1 |
| Study First Received: | October 25, 2006 |
| Last Updated: | October 2, 2008 |
| ClinicalTrials.gov Identifier: | NCT00392795 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Critical Care Delirium Long-term cognitive impairment mechanical ventilation |
Critical illness dementia sedatives and analgesics aging |
|
Central Nervous System Diseases Confusion Brain Diseases Cognition Disorders Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Critical Illness |
Mental Disorders Neurologic Manifestations Analgesics Dementia Neurobehavioral Manifestations Delirium |
|
Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Nervous System Diseases Central Nervous System Diseases Neurologic Manifestations |
Confusion Brain Diseases Dementia Neurobehavioral Manifestations Cognition Disorders Delirium |